???Inhibition of 11beta-HSD-1 represents an important new mechanism of action for treating diabetic patients,??? commented Dr. Richard Gregg, Vitae???s Chief Scientific Officer. ???This program addresses several features of the metabolic syndrome, a combination of disorders, including abdominal obesity, high blood pressure and insulin resistance or glucose intolerance, all of which contribute to a